Cargando…

The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study

AIM: Continuous renal replacement therapy (CRRT) with a cytokine‐adsorbing hemofilter (CAH) is effective in the treatment of sepsis. Two filter types, namely polymethyl methacrylate (PMMA) and surface‐treated AN69 (AN69ST) hemofilters, have been successfully used for CRRT, but no direct comparisons...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobashi, Shuichi, Maruhashi, Takaaki, Nakamura, Tomoya, Hatabayashi, Erika, Kon, Akihide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328921/
https://www.ncbi.nlm.nih.gov/pubmed/30651999
http://dx.doi.org/10.1002/ams2.382
_version_ 1783386732984532992
author Kobashi, Shuichi
Maruhashi, Takaaki
Nakamura, Tomoya
Hatabayashi, Erika
Kon, Akihide
author_facet Kobashi, Shuichi
Maruhashi, Takaaki
Nakamura, Tomoya
Hatabayashi, Erika
Kon, Akihide
author_sort Kobashi, Shuichi
collection PubMed
description AIM: Continuous renal replacement therapy (CRRT) with a cytokine‐adsorbing hemofilter (CAH) is effective in the treatment of sepsis. Two filter types, namely polymethyl methacrylate (PMMA) and surface‐treated AN69 (AN69ST) hemofilters, have been successfully used for CRRT, but no direct comparisons have been published to date. This study compared the efficacy, as measured by 28‐day survival rates, of PMMA and AN69ST hemofilters in patients receiving CAH‐CRRT. METHODS: This retrospective observational study reviewed the medical records of 142 patients who received CAH‐CRRT between November 2013 and February 2015. RESULTS: The 28‐day survival rates were higher in the AN69ST group than in the PMMA group for patients with or without sepsis (all patients, 79.4% versus 54.1%; patients with sepsis, 77.3% versus 50.0%; patients without sepsis, 83.3% versus 57.5%; P < 0.05). No significant differences were observed regarding 28‐day survival rates of patients with or without sepsis (AN69ST, 77.3% versus 83.3%; P = 0.51; PMMA, 50.0% versus 57.5%; P = 0.61) using the same hemofilter. CONCLUSION: The AN69ST hemofilter could be more effective than PMMA hemofilters for improving the survival outcomes of patients with or without sepsis.
format Online
Article
Text
id pubmed-6328921
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63289212019-01-16 The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study Kobashi, Shuichi Maruhashi, Takaaki Nakamura, Tomoya Hatabayashi, Erika Kon, Akihide Acute Med Surg Original Articles AIM: Continuous renal replacement therapy (CRRT) with a cytokine‐adsorbing hemofilter (CAH) is effective in the treatment of sepsis. Two filter types, namely polymethyl methacrylate (PMMA) and surface‐treated AN69 (AN69ST) hemofilters, have been successfully used for CRRT, but no direct comparisons have been published to date. This study compared the efficacy, as measured by 28‐day survival rates, of PMMA and AN69ST hemofilters in patients receiving CAH‐CRRT. METHODS: This retrospective observational study reviewed the medical records of 142 patients who received CAH‐CRRT between November 2013 and February 2015. RESULTS: The 28‐day survival rates were higher in the AN69ST group than in the PMMA group for patients with or without sepsis (all patients, 79.4% versus 54.1%; patients with sepsis, 77.3% versus 50.0%; patients without sepsis, 83.3% versus 57.5%; P < 0.05). No significant differences were observed regarding 28‐day survival rates of patients with or without sepsis (AN69ST, 77.3% versus 83.3%; P = 0.51; PMMA, 50.0% versus 57.5%; P = 0.61) using the same hemofilter. CONCLUSION: The AN69ST hemofilter could be more effective than PMMA hemofilters for improving the survival outcomes of patients with or without sepsis. John Wiley and Sons Inc. 2018-12-13 /pmc/articles/PMC6328921/ /pubmed/30651999 http://dx.doi.org/10.1002/ams2.382 Text en © 2018 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Kobashi, Shuichi
Maruhashi, Takaaki
Nakamura, Tomoya
Hatabayashi, Erika
Kon, Akihide
The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
title The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
title_full The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
title_fullStr The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
title_full_unstemmed The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
title_short The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
title_sort 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328921/
https://www.ncbi.nlm.nih.gov/pubmed/30651999
http://dx.doi.org/10.1002/ams2.382
work_keys_str_mv AT kobashishuichi the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT maruhashitakaaki the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT nakamuratomoya the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT hatabayashierika the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT konakihide the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT kobashishuichi 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT maruhashitakaaki 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT nakamuratomoya 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT hatabayashierika 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy
AT konakihide 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy